Investor Relations

Stock Information

Symbol: OTC: LLBO
Additional information can be obtained at:

Transfer Agent

Worldwide Stock Transfer, LLC.
One University Plaza • Suite 505 • Hackensack, NJ 07601
Phone: (201) 820-2008, Fax: (201) 820-2010 , Email:

Risk Factors

The Company’s product, the iTBra™ (formerly the First Warning System™), is in the process of preparing for a 510(k) submission to the FDA. If a 510(k) is approved, commercialization of the the iTBra™ could continue to be pursued. However, there can be no assurance that the FDA will approve the Company’s submission. There is a possibility that the FDA could reject the technology and the claims concerning the capabilities of the iTBra™. The claims to be included in the submission are expected to cover the iTBra™’s process and ability to identify breast tissue abnormalities, which may indicate cancerous or precancerous conditions.

The FDA could require the Company to conduct the testing of additional patients to validate the capabilities and claims of the iTBra™. Should additional patient testing be required, additional financing resources could, and most likely would, be necessary. There is no assurance that the Company could acquire the funding required to conduct additional patient testing.

Should the FDA clear the iTBra™‘s claims and technology as included in the 510(k) submission, there can be no assurance that the targeted markets, physicians and their patients, will adopt the process in sufficient quantities to create a commercially profitable venture, hence, impacting the companies potential future value.


About Lifeline Biotechnologies:
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV.  LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer.  Three “Proof of Concept” clinical trials of over 500 women have been completed and three patents (one hardware, two software) have been awarded. 

Safe Harbor:
This publication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.